Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
Baird Medical Investment Holdings (NASDAQ: BDMD), a leading developer of microwave ablation (MWA) medical devices, announced its participation in the American Thyroid Association (ATA) Annual Meeting from October 30 to November 3, 2024, in Chicago. The company will showcase its innovations at Booth 100 and host an Expo Theater Presentation on November 2, titled 'Latest Advancements in MWA for Thyroid Treatment'.
The presentation will feature experts from Tulane University, Sun Yat-sen University, and Houston Methodist Hospital. Baird Medical's participation highlights its expansion into the U.S. market following FDA clearance for its MWA technology, offering a minimally invasive alternative to thyroidectomy for benign thyroid tumors. With over 150,000 thyroidectomies performed annually in the U.S., Baird Medical's technology presents a safer option for patients.
Baird Medical Investment Holdings (NASDAQ: BDMD), un importante sviluppatore di dispositivi medici per l'ablazione a microonde (MWA), ha annunciato la sua partecipazione al Meeting Annuale dell'American Thyroid Association (ATA) che si svolgerà dal 30 ottobre al 3 novembre 2024 a Chicago. L'azienda presenterà le sue innovazioni allo stand 100 e ospiterà una presentazione presso l'Expo Theater il 2 novembre, intitolata 'Ultimi Progressi nell'MWA per il Trattamento della Tiroide'.
La presentazione presenterà esperti della Tulane University, della Sun Yat-sen University e dell'Houston Methodist Hospital. La partecipazione di Baird Medical evidenzia la sua espansione nel mercato statunitense dopo l'approvazione della FDA per la sua tecnologia MWA, offrendo un'alternativa mini-invasiva alla tiroidectomia per i tumori benigni della tiroide. Con oltre 150.000 tiroidectomie eseguite annualmente negli Stati Uniti, la tecnologia di Baird Medical rappresenta un'opzione più sicura per i pazienti.
Baird Medical Investment Holdings (NASDAQ: BDMD), un desarrollador líder de dispositivos médicos para ablación por microondas (MWA), anunció su participación en el Encuentro Anual de la American Thyroid Association (ATA) que se llevará a cabo del 30 de octubre al 3 de noviembre de 2024 en Chicago. La compañía presentará sus innovaciones en el Stand 100 y organizará una presentación en el Expo Theater el 2 de noviembre, titulada 'Últimos Avances en MWA para el Tratamiento de la Tiroides'.
La presentación contará con expertos de la Tulane University, la Sun Yat-sen University y el Houston Methodist Hospital. La participación de Baird Medical subraya su expansión en el mercado estadounidense tras la aprobación de la FDA para su tecnología MWA, que ofrece una alternativa mínimamente invasiva a la tiroidectomía para tumores benignos de tiroides. Con más de 150,000 tiroidectomías realizadas anualmente en los EE. UU., la tecnología de Baird Medical presenta una opción más segura para los pacientes.
베어드 메디컬 투자 소유 (NASDAQ: BDMD), 마이크로웨이브 절제(MWA) 의료 기기의 선도적인 개발업체가 미국 갑상선학회(ATA) 연례 회의에 참여한다고 발표했습니다. 이 회의는 2024년 10월 30일부터 11월 3일까지 시카고에서 열립니다. 이 회사는 부스 100에서 최신 혁신을 선보이고, 11월 2일에 '갑상선 치료를 위한 MWA의 최신 발전'이라는 주제로 엑스포 극장 발표를 주최할 예정입니다.
이 발표에는 튤레인 대학교, 선양 대학교, 휴스턴 메소디스트 병원의 전문가들이 참여할 것입니다. 베어드 메디컬의 참여는 FDA의 MWA 기술 승인을 바탕으로 미국 시장으로의 확장을 강조합니다. 이 기술은 양성 갑상선 종양에 대한 갑상선 절제술을 대체하는 최소 침습적 방법을 제공합니다. 미국에서 매년 150,000건 이상의 갑상선 절제술이 시행되므로, 베어드 메디컬의 기술은 환자에게 더 안전한 옵션을 제공합니다.
Baird Medical Investment Holdings (NASDAQ: BDMD), un développeur de premier plan de dispositifs médicaux d'ablation par micro-ondes (MWA), a annoncé sa participation à la Réunion Annuelle de l'American Thyroid Association (ATA) qui se tiendra du 30 octobre au 3 novembre 2024 à Chicago. L'entreprise présentera ses innovations au Stand 100 et animera une présentation au théâtre Expo le 2 novembre, intitulée 'Dernières Avancées en MWA pour le Traitement de la Thyroïde'.
La présentation mettra en vedette des experts de l’Université de Tulane, de l’Université Sun Yat-sen et de l’Hôpital Méthodiste de Houston. La participation de Baird Medical souligne son expansion sur le marché américain après l'approbation de la FDA pour sa technologie MWA, offrant une alternative mini-invasive à la thyroïdectomie pour les tumeurs thyroïdiennes bénignes. Avec plus de 150 000 thyroïdectomies réalisées chaque année aux États-Unis, la technologie de Baird Medical représente une option plus sûre pour les patients.
Baird Medical Investment Holdings (NASDAQ: BDMD), ein führender Entwickler von Mikrowellenablations (MWA) medizinischen Geräten, gab seine Teilnahme an der Jahrestagung der American Thyroid Association (ATA) bekannt, die vom 30. Oktober bis 3. November 2024 in Chicago stattfinden wird. Das Unternehmen wird seine Innovationen am Stand 100 präsentieren und am 2. November eine Expo-Theater-Präsentation mit dem Titel 'Neueste Fortschritte in MWA zur Behandlung von Schilddrüsenerkrankungen' halten.
Die Präsentation wird Experten der Tulane University, der Sun Yat-sen University und des Houston Methodist Hospital präsentieren. Die Teilnahme von Baird Medical unterstreicht die Expansion in den US-Markt nach der FDA-Zulassung für seine MWA-Technologie, die eine minimalinvasive Alternative zur Schilddrüsenoperation bei gutartigen Schilddrüsentumoren bietet. Mit über 150.000 Schilddrüsenoperationen, die jährlich in den USA durchgeführt werden, stellt die Technologie von Baird Medical eine sicherere Option für Patienten dar.
- None.
- None.
Baird Medical will showcase its innovations at Booth 100, one of the largest exhibitor spaces at the event, featuring the Company's latest advancements in MWA technology and highlighting its impact on thyroid care. During the event, the Company will also host an Expo Theater Presentation on November 2, 2024, from 10:25 AM to 11:25 AM, inside the Exhibit Hall of the Chicago Ballroom. The session, titled "Latest Advancements in MWA for Thyroid Treatment," will provide valuable insights into recent developments in this field. It will feature Dr. Emad Kandil from Tulane University, Dr. Feng Than from Sun Yat-sen University, and Dr. Khadra Helmi from Houston Methodist Hospital.
"We are excited to participate in the ATA Annual Meeting and present our innovations in microwave ablation technology," said Haimei Wu, Co-Founder of Baird Medical. "This event is an excellent opportunity to engage with leading experts and foster meaningful relationships to advance thyroid care. We warmly invite all attendees to visit our booth and attend our Expo Theater Presentation to explore our cutting-edge MWA technology."
Baird Medical's participation in the event underscores its expansion into the U.S. market, following a successful listing on the Nasdaq exchange. The Company's recent FDA clearance for its minimally invasive microwave ablation technology offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. With over 150,000 thyroidectomies performed annually in the
About the ATA® Annual Meeting
The ATA® Annual Meeting is the world's preeminent event for those interested in thyroid diseases and disorders. It's an opportunity for peer-to-peer learning and collaboration through lectures, interactive discussions, meet the professor sessions, and abstracts.
About Baird Medical
Established in 2012 and headquartered in
Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com
Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com
View original content:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-the-american-thyroid-association-ata-annual-meeting-302275013.html
SOURCE Baird Medical Investment Holdings Ltd.
FAQ
When and where is Baird Medical (BDMD) participating in the ATA Annual Meeting?
What will Baird Medical (BDMD) showcase at the ATA Annual Meeting?
When is Baird Medical's (BDMD) Expo Theater Presentation at the ATA Annual Meeting?